Outcomes of cardiovascular screening in men aged 60–64 years

 📚 ESC 2025 Coverage: Targeting Hypercontractility in Nonobstructive HCM: A Place for Mavacamten? by Dr. Sharif Kashani, Fellowship of Heart Failure....

📚 ESC 2025 Coverage: Do Drug-Coated Devices Offer More Than Just a High Price Tag in PAD? by Dr. Sadeghipour, Interventional Cardiologist....

📚 ESC 2025 Coverage: When the Stakes Are Higher: Exploring Flu Vaccine Potency in Older Populations by Dr. Motaghizadeh, Cardiovascular Specialist....

📚 ESC 2025 Coverage: When Three Drugs Aren’t Enough: Exploring Baxdrostat in Resistant Hypertension by Dr. Ghanavati, Cardiovascular Specialist....

📚 ESC 2025 Coverage: Expanding the Benefit Zone: Can β Blockers Help Post-MI Patients with Mildly Reduced Ejection Fraction? by Dr. Yahyavi, Cardiovascular Researcher....

📚 ESC 2025 Coverage: The SMuRF-less Illusion: Inflammation Unmasks Hidden Cardiovascular Risk in Healthy Women, by Dr. Hafezi, Cardiovascular Specialist....

📚 ESC 2025 Coverage: A Classic Revived: Digitoxin Lowers Risk in HFrEF When Added to Modern Therapy, by Dr. Talasaz, Clinical Pharmacist....

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy...

📚 ESC 2025 Coverage: All at Once or One Step at a Time? Immediate Revascularisation Falls Short of Non-Inferiority in STEMI Patients, by Dr. Soltani Moghadam, Cardiovascular Researcher....